The 78 kilodalton
glucose-regulated
protein (
GRP78) is a major endoplasmic reticulum (ER)
molecular chaperone with antiapoptotic properties and a key regulator of the unfolded protein response (UPR). ER-stress induction of
GRP78 in
cancer cells represents a major pro-survival branch of the UPR. Pancreatic ductal
adenocarcinoma (PDAC) remains a highly lethal disease and high level of
GRP78 is associated with aggressive disease and poor survival. Recently, we reported that PDAC exhibited high level of ER stress and that
GRP78 haploinsufficiency is sufficient to suppress pancreatic
tumorigenesis in mice, suggesting the utility of inhibitors of
GRP78 expression in combating
pancreatic cancer. Screening of clinically relevant compound libraries revealed that
cardiac glycosides (CGs) can inhibit ER-stress induction of
GRP78 in pancreatic and other types of human
cancers. Using the FDA-approved CG compound
Lanatoside C (LanC) and human
pancreatic cancer cell lines as model systems, we discovered that LanC preferably suppressed ER stress induction of
GRP78 and to a lesser extent
GRP94. The suppression is at the post-transcriptional level and dependent on the Na+/K+-
ATPase ion pump. Overexpression of
GRP78 mitigates apoptotic activities of LanC in ER stressed cells. Our study revealed a new function of CGs as inhibitor of stress induction of
GRP78, and that this suppression at least in part contributes to the apoptotic activities of CGs in human
pancreatic cancer cells in vitro. These findings support further investigation into CGs as potential
antineoplastic agents for pancreatic and other
cancers which depend on
GRP78 for growth and survival.